secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K/A
Filed at:   2025-08-26T23:59:59+00:00
Accession:  0001615219-25-000115
Event type: m_and_a
Sentiment:  negative
Materiality: 0.75
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius amends merger with Decoy; legacy holders diluted to 7.6%
-----------------------------------------------------------------

- Effective ownership post-merger: Salarius legacy holders 7.6%, Decoy holders 92.4% (pre-Qualified Financing).
- Salarius valuation reduced from $4.6M to $2.31M in Amendment 2; Decoy valued at $28M.
- Qualified Financing requires minimum $6M; expected $8M from 1,470,588 shares at $5.44/share.
- Amendment 4 removes threshold for anti-dilution adjustments; applies until Nasdaq listing & shareholder approval.
- Merger accounted for as reverse asset acquisition with Decoy as accounting acquirer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000115/0001615219-25-000115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000115/flks-20250822.htm
  HTML page:      https://secwatch.observer/filing/0001615219-25-000115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer